The company is conducting the final analysis on the Phase I clinical data
(expected by year-end), with a follow-up Phase 1b proof-of-concept trial in
1H16. Recall that Rock Creek's regulatory strategy is to complete a single-site
Phase Ib/IIa trial in EU and prepare data for a multi-site Phase IIb trial including
in the U.S. The FDA's approval for the Phase IIb trial is expected in 2016.
“the Company is communicating with the scientific and medical community for potential collaborative and independent, investigative study for autism spectrum and related disorders.”
The Company IS communicating with......
IS COMMUNICATING with ...
Hog on that one shorts!
Chronic Anatabine Treatment Reduces
Alzheimer’s Disease (AD)-Like Pathology and
Improves Socio-Behavioral Deficits in a
Transgenic Mouse Model of AD
Published: May 26, 2015
I wonder what they will think about the news the US GOVERNMENT is helping to fund Anatabine research?
My guess is Roskamp will be using the new time release formulation that was developed in the UK clinical trial. It is only logical that the effectiveness of anatabine is increased significantly via a time release formulation.
Overall, I think it is very significant that Roskamp was able to convince the Government to fund this new anatabine trial. It says a lot about the safety and research data that has been collected to date.
It is obviously good news that anatabine research is now on two parallel development paths, a Psoriasis path and a Gulf War study path. This is going to attract more investors in my opinion.
Drummy used to rent a goat but a judge had to step in and issue a restraining order.
Believe me, you don’t want to know the details.
Now that the company has the cash to continue operations and conduct clinical trails..
meanwhile the shorts continue to pay interest on those borrowed shares..